Biogen pays California biotech $350M upfront for Alzheimer’s gene therapy

As the world waits for Biogen to submit what could be the first new Alzheimer’s disease drug in several years, the Cambridge drugmaker has struck a deal to develop at least one more potential treatment for the memory-deteriorating disease.